SciRhom GmbH is at the forefront of developing innovative biopharmaceuticals targeting autoimmune diseases through its proprietary iRhom2 antibodies. The company has focused on the enzyme TACE (TNF-alpha converting enzyme), which plays a crucial role in various inflammatory signaling pathways. By creating first-in-class humanized antibodies against iRhom2, SciRhom aims to inhibit TACE selectively in immune cells, thereby blocking multiple pro-inflammatory pathways, including TNF-alpha and IL-6R signaling. This novel approach not only demonstrates superior efficacy in preclinical models of rheumatoid arthritis and inflammatory bowel disease but also aims to maintain a favorable safety profile, potentially outperforming existing treatments.

The lead candidate, SR-878, has recently progressed to the clinical trial phase, with a Clinical Trial Application submitted for first-in-human studies. This milestone reflects SciRhom's commitment to translating extensive research into effective therapies. The company has established a robust biopharmaceutical manufacturing process in collaboration with WuXi Biologics, ensuring high-quality production of SR-878. With a strong patent portfolio securing exclusivity for its anti-iRhom2 antibodies, SciRhom is well-positioned to advance its pipeline, which includes indications such as lupus nephritis and dermatological diseases, while continuing to explore the therapeutic potential of iRhom2 across various medical fields.

Germany

SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.

SciRhom

Company Details